I have to tell you (and you can believe or not - no proof to offer) - I've been accused of many things, but emotional was never one of them. Maybe a lack of once in a while :)
I agree with some of what you said and realized long ago there are many things the company, the ceo and officers can do better.
But that's also the crucks of what my message was about - while Leronlimab needs to have a trial (or two or three) come together in a fashion that includes proper power, patient distribution, primary/secondary endpoints etc. - there are all the signals in the world to prove desirable bioactivity is taking place as the product interacts with the body.
While my own acid enjoyed digesting parts of my stomach lining over the past couple of years (and no - not all as a fault of Nader) - the learnings achieved from veering off-course to Covid and developing a comprehensive understanding of the association of CCR5 inhibition and autoimmune/infectious disease/cancer mechanisms may have opened a much wider and nearer-term window into a platform play that was nowhere in sight (in terms of practical cellular/biological level interaction understanding) just 18 months ago. Sometime a wayward trip, though unintended and taken by combination of mistakes and circumstances, can end up getting you to a location you never realized you can attain.
And that, in general, means it should never go away, get to zero, or any other nonsense thrown by individuals who's sole objective is to gain from a diminished stock value and use anything from pseudo-science to outright fabricated nonsense and coordinated attacks to achieve that effect.
I'm unable to predict where the value will be a year or two from now but can tell you (educated opinion of course) that in a fire sale it would fetch an order of magnitude above its current market value.
As long as some of the variables align over the next few months no investor should have to worry about a fire sale.
AI
Market Data 
Markets 
